• Issue
    Volume 54, Issue 4
    April 2024


Free Access

Issue Information

  • Pages: 235-237
  • First Published: 18 April 2024


Open Access

Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy

  • Pages: 241-252
  • First Published: 08 February 2024
Description unavailable

Ocular surface disease is very common in AD patients, and not all patients reported ocular symptoms. Less conjunctival goblet cells were found in AD patients compared to healthy controls. During dupilumab treatment, approximately 30% of the dupilumab-treated AD patients developed dupilumab-associated ocular surface disease. Stable but low conjunctival goblet cell numbers were found, with a decrease in the Mucin 5AC production. Clinicians should be aware of (DA)OSD in AD patients.


Open Access

Long-term effects of pollen allergoid tyrosine-adsorbed subcutaneous immunotherapy on allergic rhinitis and asthma

  • Pages: 253-264
  • First Published: 26 December 2023
Description unavailable

Long-term benefit (up to 9.5 years) of authorized pollen allergoid SCIT including tyrosine-adsorbed allergoids in children/adolescents and adults. Significantly more patients without Allergic Rhinitis (AR) and Asthma (AA) medication prescription in follow-up. Significantly reduced AR and AA medication prescriptions and probability of asthma onset in follow-up.

Open Access

Protein–Protein interactive networks identified in bronchoalveolar lavage of severe compared to nonsevere asthma

  • Pages: 265-277
  • First Published: 22 January 2024
Description unavailable

Proteomic assay of asthma BALF found increased and decreased proteins differentiating severe and nonsevere asthma groups. Protein-protein interactions confirmed airway remodeling, receptor signaling and leukocyte recruitment to severe asthma airways.

Open Access

Easy assessment of the avidity of polyclonal allergen-specific serum antibodies

  • Pages: 278-285
  • First Published: 06 January 2024
Description unavailable

Complexes of antibodies with allergens were disrupted by acidic buffers in ELISA. Residual antibodies were expressed as the percentage of antibodies bound at neutral conditions set to 100%. Dissociation curves were created and the avidity index (the pH value that dissociated 50% of antibodies) was calculated. The modified ELISA can be used to estimate the net-binding force of allergen-specific polyclonal IgG antibodies in serum.